Both methods are highly sensitive (88–96%) and specific (83–98%) for α-synuclein aggregates and Lewy-body pathology in PD and DLB as assessed in matched CSF/brain samples compared to healthy controls and other forms of dementia and parkinsonism (Rossi et al. 2020; Kang et al. 2019). The gene discussed is SNCA; the disease is dementia.